Antioxidant Status in Schizophrenic Patients

被引:0
|
作者
Mahmood, Isam Hamo [1 ]
Abdullah, Kasim Salih [1 ]
Khattab, Ilham [1 ]
机构
[1] Univ Mosul, Coll Med, Dept Med & Pharmacol, Mosul, Iraq
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To measure the concentration of total antioxidant status (TAS) in a number of chronic schizophrenic patients and to compare the results with those of healthy controls. Design: Case-control study. Setting: The College of medicine and Al-Salam hospital in Mosul. Method: Twenty patients meeting DSM-IV criteria for schizophrenia, and twenty age and sex-matched healthy volunteers. Total antioxidant status (TAS) was measured in both groups. Result: Mean antioxidant status of the schizophrenic group was 1.15+/-0.39 mmol/l (Range 0.5 to 1.8 mmol/l) while those of the control group, mean was 1.96+/-0.13 mmol/l (Range 1.76 to 2.26 mmol/l). The difference between the two means was statistically significant (P< 0.001). Conclusion: The present study demonstrated that schizophrenic patients have low levels of TAS. It further emphasizes the growing consideration that oxidative damage may occur in schizophrenic patients that exhaust the antioxidant defense of the body leading to low levels of TAS.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Antioxidant status in canine cancer patients
    Plavec, Tanja
    Nemec, Svete Alenka
    Butinar, J.
    Tozon, Natasa
    Prezelj, Marija
    Kandel, Bettina
    Kessler, M.
    [J]. ACTA VETERINARIA-BEOGRAD, 2008, 58 (2-3): : 275 - 286
  • [32] Antioxidant status in cystic fibrosis patients
    WinklhoferRoob, BM
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 63 (01): : 138 - 139
  • [33] Pathophysiology and antioxidant status of patients with fibromyalgia
    Riffat Iqbal
    M. S. Mughal
    Najma Arshad
    Muhammad Arshad
    [J]. Rheumatology International, 2011, 31 : 149 - 152
  • [34] The antioxidant status of breast cancer patients
    Korman, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S119 - S119
  • [35] The relationship between antipsychotic use and plasma antioxidant levels in schizophrenic patients
    Dilbaz, N.
    Pazvantoglu, O.
    Okay, T.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S273 - S273
  • [36] Methylation status of the reelin promoter region in the brain of schizophrenic patients
    Tochigi, Mamoru
    Iwamoto, Kazuya
    Bundo, Miki
    Komori, Atsuko
    Sasaki, Tsukasa
    Kato, Nobumasa
    Kato, Tadafumi
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (05) : 530 - 533
  • [37] Structural and metabolic status and functional properties of erythrocytes in schizophrenic patients
    Ryazantseva, NV
    Novitsky, VV
    [J]. ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2002, 102 (06): : 36 - 42
  • [38] NIGHT-TIME/DAY-TIME ANTIOXIDANT STATUS LEVELS IN PARANOID SCHIZOPHRENIC INPATIENTS
    Diaz Mesa, E.
    Morera Fumero, A.
    Abreu Gonzalez, P.
    Jimenez Sosa, A.
    Henry, M.
    Fernandez Lopez, L.
    Gracia Marco, R.
    [J]. EUROPEAN PSYCHIATRY, 2012, 27
  • [39] Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients
    Miljevic, Cedo D.
    Nikolic-Kokic, Aleksandra
    Blagojevic, Dusko
    Milovanovic, Maja
    Munjiza, Ana
    Jukic, Marin M.
    Pesic, Vesna
    Lecic-Tosevski, Dusica
    Spasic, Mihajlo B.
    [J]. PSYCHIATRY RESEARCH, 2018, 269 : 746 - 752
  • [40] Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients
    Raffa, Monia
    Mechri, Anwar
    Ben Othman, Leila
    Fendri, Chiraz
    Gaha, Lotfi
    Kerkeni, Abdelhamid
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (07): : 1178 - 1183